Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TachoSil for prevention of postoperative complications after groin dissection in vulvar cancer
2016-001191-30Phase 2Completed
- Sponsor
- Department of Obstetrics & Gynecology, Copenhagen University Hospital, Rigshospitalet
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of tachosil in Vulval carcinoma (2 arms), sponsored by Department of Obstetrics & Gynecology, Copenhagen University Hospital, Rigshospitalet. Primary endpoint: Incidence of symptomatic lymphocele. Started Mar 2017; status: completed.
02
Drugs
tachosil
03
Conditions
Vulval carcinoma
Beyond the preview
Go deeper on 2016-001191-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001191-30.